StockData
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. (TRVI) stock

TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$13.29−0.36 (-2.64%)

Close on Nov 16, 2026Market cap $1.89BP/E –Yield –

Trevi Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Trevi Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $41.37M, up 9.6% year over year. For fiscal 2025 it was $33.48M, down 15.0% from the year before. The highest annual figure on record is $39.38M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$33.48M-15.0%
FY2024Dec 31, 2024$39.38M+66.3%
FY2023Dec 31, 2023$23.68M+19.4%
FY2022Dec 31, 2022$19.83M-13.7%
FY2021Dec 31, 2021$22.98M+2.9%
FY2020Dec 31, 2020$22.33M+15.5%
FY2019Dec 31, 2019$19.34M+37.4%
FY2018Dec 31, 2018$14.07M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$15.15M+61.4%
Q1 FY2026Mar 31, 2026$9.94M+27.3%
Q4 FY2025Dec 31, 2025$6.19M-33.6%
Q3 FY2025Sep 30, 2025$10.09M-10.1%
Q2 FY2025Jun 30, 2025$9.39M-6.3%
Q1 FY2025Mar 31, 2025$7.81M-11.3%
Q4 FY2024Dec 31, 2024$9.33M+43.1%
Q3 FY2024Sep 30, 2024$11.22M+77.5%
Q2 FY2024Jun 30, 2024$10.02M+71.5%
Q1 FY2024Mar 31, 2024$8.80M+76.1%
Q4 FY2023Dec 31, 2023$6.52M+51.0%
Q3 FY2023Sep 30, 2023$6.32M+9.6%
Q2 FY2023Jun 30, 2023$5.84M+14.5%
Q1 FY2023Mar 31, 2023$5.00M+7.6%
Q4 FY2022Dec 31, 2022$4.32M-30.1%
Q3 FY2022Sep 30, 2022$5.77M+22.3%
Q2 FY2022Jun 30, 2022$5.10M-21.5%
Q1 FY2022Mar 31, 2022$4.65M-16.9%
Q4 FY2021Dec 31, 2021$6.18M-5.8%
Q3 FY2021Sep 30, 2021$4.72M-2.3%
Q2 FY2021Jun 30, 2021$6.50M+32.0%
Q1 FY2021Mar 31, 2021$5.59M-7.1%
Q4 FY2020Dec 31, 2020$6.56M+36.0%
Q3 FY2020Sep 30, 2020$4.83M-14.5%
Q2 FY2020Jun 30, 2020$4.92M-11.0%
Q1 FY2020Mar 31, 2020$6.02M+80.3%
Q4 FY2019Dec 31, 2019$4.82M+6.6%
Q3 FY2019Sep 30, 2019$5.65M+50.8%
Q2 FY2019Jun 30, 2019$5.53M+60.7%
Q1 FY2019Mar 31, 2019$3.34M+41.3%
Q4 FY2018Dec 31, 2018$4.52M–
Q3 FY2018Sep 30, 2018$3.75M–
Q2 FY2018Jun 30, 2018$3.44M–
Q1 FY2018Mar 31, 2018$2.36M–

More Trevi Therapeutics figures

See a number that looks wrong?